- Analysts have revised their outlooks for Boston Scientific, with firms like Truist Financial and Wells Fargo lowering price targets and ratings.
- The primary concern stems from anticipated flat revenue growth in the company’s key Watchman heart implant product line.
- Despite these challenges, Boston Scientific management reaffirms its full-year 2026 organic revenue growth guidance, signaling confidence in its broader medical device portfolio.
Boston Scientific (NYSE:BSX) is a global developer and manufacturer of medical devices used in various medical specialties. The company faces a revised investment outlook from analysts, with Truist Financial lowering its price target on Boston Scientific to $64.00 from $85.00. At the time of the update, the stock was trading at $49.35, suggesting a potential 29.7% upside.
The adjustment follows comments from CEO Mike Mahoney, who acknowledged weakness in Boston Scientific’s Watchman heart implant product line. He projects that revenue from these products will likely be flat in the current and next quarters. This is due to a shift toward performing the implant procedure alongside other surgeries rather than as a standalone operation.
This sentiment is shared by other equity analysts. As highlighted by Benzinga, Wells Fargo downgraded Boston Scientific from an Overweight to an Equal-Weight rating. An Overweight rating suggests a stock is a better value than others, while Equal-Weight implies it will perform in line with its sector. The analyst also cut the price target from $75.00 to $55.00.
These analyst actions occurred as shares of Boston Scientific fell 15% over the week. The stock currently trades at $49.30, near its 52-week low of $47.17 and significantly below its high of $109.50. The company has a market capitalization, which is the total value of all its shares, of approximately $73.28 billion.
Despite the concerns, Boston Scientific management maintains its full-year 2026 guidance. They still expect organic revenue growth, which is growth generated from the company’s existing operations, to be between 6.5% and 8%. This indicates confidence in other areas of the medical technology business to offset the slowdown in the Watchman line.
